First Quarter Earnings Dampened By Severe Weather
This article was originally published in The Pink Sheet Daily
Executive Summary
Keryx cautions investors that a Zerenex approval is not guaranteed; NPS reports sluggish Gattex sales; Eylea sales down, but expected to rebound with new indications in the second half; Ariad’s Iclusig relaunch off to a good start.
You may also be interested in...
Regeneron Touts Potential Of Growing Eylea Franchise After Robust Q4
Speaking at the J.P. Morgan meeting in January, Regeneron CEO Leonard Schleifer says the company is exploring many opportunities to build the franchise around its successful wet AMD drug Eylea. In the fourth quarter, the drug racked up $400 million in U.S. sales, beating expectations.
Zerenex To Be Positioned As Cost-Saving, Oral Alternative In ESRD Setting
Keryx plans to file an NDA for phosphate binder Zerenex during the second quarter, with an EU filing to follow by mid-year. In a long-term Phase III study, the candidate met its primary efficacy endpoint as well as several secondary endpoints.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.